Please provide your email address to receive an email when new articles are posted on . Investigational therapies to lower Lp(a) include antisense oligonucleotide therapies and small interfering RNA ...

Lp(a) lipoprotein binds proinflammatory oxidized phospholipids. We investigated whether levels of oxidized low-density lipoprotein (LDL) measured with use of monoclonal antibody E06 reflect the ...

CHICAGO, IL—Two new drugs targeting lipoprotein(a)—one a small interfering RNA (siRNA), the other an oral agent that prevents its formation—both showed positive results in early phase II studies, with ...

Please provide your email address to receive an email when new articles are posted on . Lipoprotein(a) should be measured in all people at least once. “Evaluation and management of Lp(a) is actionable ...

Both lipoprotein(a) and coronary artery calcium (CAC) are independently associated with an increased risk of atherosclerotic cardiovascular disease, with the highest risk seen among people with ...

Millions of Americans are born genetically predisposed to extremely high levels of a type of cholesterol that cause deadly heart attacks and strokes by middle age, yet they are almost always unaware ...

The evidence implicating high levels of lipoprotein(a), or Lp(a), as a risk predictor for heart attack, stroke, and other cardiovascular conditions has outpaced the science of what to do about the ...

CHICAGO — The remarkable and sustained reductions in lipoprotein(a) ( Lp[a]) achieved with lepodisiran (Eli Lilly) , a novel small-interfering (si)RNA molecule, in a phase 2 trial might signal a major ...

An increased level of Lp(a) lipoprotein has been identified as a risk factor for coronary artery disease that is highly heritable. The genetic determinants of the Lp(a) lipoprotein level and their ...

NASHVILLE, Tenn., April 09, 2025--(BUSINESS WIRE)--LP Building Solutions (LP), a leading manufacturer of high-performance building products, today announced the launch of its Naturals Collection™—a ...